BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Immune Response BioPharma Provides Blockbuster RAVAX Phase III Study in RA Update


7/6/2012 10:09:31 AM

PRLog (Press Release) - Jul 05, 2012 - Immune Response BioPharma, Inc. Provides RAVAX Phase III Study in RA Update With Inadequete Response to Humira or Enbrel now Available online at www.immuneresponse.net or Skydrive Live @ https://skydrive.live.com/redir?resid=310AB990382AE320!126

Immune Response BioPharma, Inc. estimates we should be begin recruiting for the new Phase III RAVAX study by year end. Our IND should be filed within 60-90 days and the official trial should be uploaded to clinicaltrials.gov once finalized. The trial will test efficacy, safety and tolerance of RAVAX with Methotrexate for 12 months and a minimum of 500-1000 patients total who get the RAVAX drug. IRBP will first test RAVAX with Methotrexate with a sufficient amount of patients to fully access the first in class and best in class RA Vaccine. IRBP is targeting a minimum of 10% market share by 2016-2017 time frame.

"RAVAX is a game changer with a safe once a month dosing compared to current RA treatments such as Humira or Enbrel which our new study will help treat patients who fail those drugs. I would expect this trial to be oversubscribed once up and running and recruiting hopefully by year end. " IRBP CEO Mr. Buswell.

"Hopefully we enter into a corporate partnership rather quickly. Any pharma with current RA drugs or those going off patent or any who don't have a potential blockbuster RA drug like RAVAX would be foolish to not partner with IRBP. RAVAX will create winners and losers in this space. The winners will be the corporate partner and of course patients" IRBP CEO Mr. Buswell.

"We are cautiously optimistic we complete a deal in the near future for our wonderful RA Vaccine treatment RAVAX. Additionally we believe RAVAX can be treatment of choice for RA patients under 10 years of diagnosed RA. We are actively discussing potential partnership opportunities with big pharma to co-develop RAVAX and fund the Phase III Study. I am confident IRBP will secure a corporate partner sooner rather than later for RAVAX and eventually get the first RA Vaccine through the clinical process and FDA approved to help those patients suffering from this debilitating disease" IRBP CEO Mr. Buswell.

Immune Response BioPharma, Inc. maybe found on the World WideWeb at www.immuneresponsebiopharma.com or our shorter URL @ www.immuneresponse.net RAVAX Study Available @ https://skydrive.live.com/redir?resid=310AB990382AE320!126



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES